Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Nephrology and Critical Care Medicine
• Neurocritical Care Therapeutics

Background:

• Levetiracetam, a key antiseizure drug, is predominantly renally eliminated.
• Kidney function critically influences levetiracetam pharmacokinetics.
• Augmented renal clearance (ARC), common in critical care, can alter drug disposition.

Purpose of the Study:

• Characterize levetiracetam pharmacokinetics in neurocritical care patients.
• Identify factors affecting levetiracetam clearance, including ARC.
• Develop optimized dosing strategies for levetiracetam in patients with and without ARC.

Main Methods:

• Prospective, observational, multicenter study of neurocritical care patients.
• Plasma levetiracetam levels measured via HPLC.
• Measured creatinine clearance (mCLCR) determined by 8-h urine collection.
• Population pharmacokinetic modeling and Monte Carlo simulations used for analysis.

Main Results:

• 35 out of 50 patients (70%) exhibited ARC.
• Lower trough levetiracetam levels observed in patients with ARC (4.4 mg/L) versus no ARC (11.8 mg/L).
• Measured CLCR significantly impacted levetiracetam clearance; initial 500 mg BID dose found insufficient.
• Simulations suggest 1500 mg BID for mCLCR ≥ 90 mL/min/1.73 m², and 1250 mg BID for mCLCR 60-89 mL/min/1.73 m².

Conclusions:

• ARC significantly enhances levetiracetam clearance in neurocritical care settings.
• Standard levetiracetam dosing (500 mg BID) is inadequate for patients with ARC.
• Higher initial doses (e.g., 1500 mg BID) are recommended for patients with ARC to achieve therapeutic concentrations.